Acta Neuropathologica

, Volume 82, Issue 4, pp 260–265 | Cite as

Immunoreactivity of cerebral amyloidosis is enhanced by protein denaturation treatments

  • R. Doi-Yi
  • T. Kitamoto
  • J. Tateishi
Regular Papers
Received:
Revised:
Accepted:

Summary

We investigated paraffin-embedded brain sections from three patients with Gerstmann-Sträussler syndrome and three patients with Alzheimer's disease or senile dementia of Alzheimer type using anti-human prion protein antisera and anti-β/A4 protein antisera after protein denaturation treatments. After incubation with guanidine-thiocyanate, trichloroacetate, and phenol, the immunoreactivity of kuru plaques and senile plaques was enhanced to the same level as the formic acid treatment. These treatments revealed small compact amyloid deposits, amyloid deposits surrounding the plaque cores, and diffuse plaques. Most of these chemicals changed the congophilia of both amyloids. It is possible that these treatments denature amyloid fibril proteins and break down the structure of amyloid fibrils, thus revealing buried epitopes.

Key words

Immunohistochemistry Gerstmann-Sträussler syndrome Alzheimer's disease Kuru plaque Senile plaque 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bendheim PE, Barry RA, DeArmond SJ, Stites DP, Prusiner SB (1984) Antibodies to a scrapie prion protein. Nature 310:418–421Google Scholar
  2. 2.
    Bruce ME, Mcbride PA, Farguhar CF (1989) Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci Lett 102:1–6Google Scholar
  3. 3.
    Curran RC, Gregory J (1978) Demonstration of immunoglobulin in cryostat and paraffin sections of human tonsil by immunofluorescence and immunoperoxidase techniques. J Clin Pathol 31:974–983Google Scholar
  4. 4.
    Doh-ura K, Tateishi J, Sasaki H, Kitamoto T, Sakaki Y (1989) PRO→LEU change at position 102 of prior protein is the most common but not the sole mutation related to Gerstmann-Sträussler syndrome. Biochem Biophys Res Commun 163:974–979Google Scholar
  5. 5.
    Doh-ura K, Tateishi J, Kitamoto T, Sasaki H, Sakaki Y (1990) Creutzfeldt-Jakob disease patients with congophilic kuru plaques have the missense variant prion protein common to Gerstmann-Sträussler syndrome. Ann Neurol 27:121–126Google Scholar
  6. 6.
    Gajdusek DC, Gibbs CJ Jr, Alpers M (1966) Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 209:794–796Google Scholar
  7. 7.
    Gibbs CJ Jr, Gajdusek DC, Asher DM, Alpers MP (1968) Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161:388–389Google Scholar
  8. 8.
    Glenner GG, Wong CW (1984) Alzheimer disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890Google Scholar
  9. 9.
    Kitamoto T, Tateishi J (1988) Immunohistochemical confirmation of Creutzfeld-Jakob disease with a long clinical course with amyloid plaque core antibodies. Am J Pathol 131:435–443Google Scholar
  10. 10.
    Kitamoto T, Tateishi J, Tashima T, Takeshita I, Barry RA, DeArmond SJ, Prusiner Sb (1986) Amyloid plaques in Creutzfeldt-Jakob disease stain with prion protein antibodies. Ann Neurol 20:204–208Google Scholar
  11. 11.
    Kitamoto T, Ogomori K, Tateishi J, Prusiner SB (1987) Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 57:230–236Google Scholar
  12. 12.
    Kitamoto T, Tateishi J, Sato Y (1988) Immunohistochemical verification of senile and Kuru plaques in Creutzfeldt-Jakob disease and allied disease. Ann Neurol 24:537–542Google Scholar
  13. 13.
    Koike F, Kunishita T, Nakayama H, Tabira T (1988) Immunohistochemical study of Alzheimer's disease using antibodies to synthetic amyloid and fibronectin. J Neurol Sci 85:9–15Google Scholar
  14. 14.
    Kretzchimar HA, Stowring LE, Westaway D, Stubblebine WH, Prusiner SB, DeArmond SJ (1986) Molecular cloning of a human prion protein cDNA. DNA 5:315–324Google Scholar
  15. 15.
    Masters CL, Gajdusek DC, Gibbs CJ Jr (1981) Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome with an analysis of the various forms of amyloid plaque deposition in the virus induced spongiform encephalopathies. Brain 104:559–588Google Scholar
  16. 16.
    Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc Natl Acad Sci USA 82:4245–4249Google Scholar
  17. 17.
    Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, Abe M (1989) β-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol 134:243–251Google Scholar
  18. 18.
    Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136–144Google Scholar
  19. 19.
    Prusiner SB, Bolton DC, Groth DF, Bowman KA, Cochran SP, McKinley MP (1982) Further purification and characterization of scrapie prions. Biochemistry 21:6942–6950Google Scholar
  20. 20.
    Prusiner SB, Groth DF, McKinley MP, Cochran SP, Bowman KA, and Kasper KC (1981) Thiocyanate and hydroxyl ions inactivate the scrapie agent. Proc Natl Acad Sci USA 78:4606–4610Google Scholar
  21. 21.
    Rumble B, Retallach R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320:1446–1452Google Scholar
  22. 22.
    Serban D, Taraboulos A, DeArmond SJ, Prusiner SB (1990) Rapid detection of CJD and scrapie prion proteins. Neurology 40:110–117Google Scholar
  23. 23.
    Shin R, Ogomori K, Itamoto T, and Tateishi J (1989) Increased tau accumuration in senile plaques as a hallmark in Alzheimer's disease. Am J Pathol 134:1365–1371Google Scholar
  24. 24.
    Tagliavuni F, Giaccone G, Frangione B, Bugiani O (1988) Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neourosci Lett 93:191–196Google Scholar
  25. 25.
    Taraboulos A, Serban D, Prusiner SB (1990) Scrapie prion proteins accumulate in the cytoplasm of perisistently infected cultured cells. J Cell Biol 110:2117–2132Google Scholar
  26. 26.
    Tashima T, Kitamoto T, Tateishi J, Sato Y (1986) Congophilia in cerebral amyloidosis is modified by inactivation procedures on slow transmissible pathogens. Brain Res 399:80–86Google Scholar
  27. 27.
    Tateishi J, Ohta M, Koga M, et al (1979) Transmission of chronic spongiform encephalopathy with kuru plaques from humans to small rodents. Ann Neurol 5:581–584Google Scholar
  28. 28.
    Tateishi J, Koga M, Sato Y, et al (1980) Properties of the transmissible agent derived from chronic spongiform encephalopathy. Ann Neurol 7:390–391Google Scholar
  29. 29.
    Tateishi J, Kitamoto T, Hashiguchi H, Shii H (1988) Gerstmann-Sträussler-Scheinker disease: immunohistological and experimental studies. Ann Neurol 24:35–40Google Scholar
  30. 30.
    Vinters H, Pardridge WM, Scor DL, Ishii N (1988) Immunohistochemical study of cerebral amyloid angiopathy. Enhancement of immunostaining using formic acid pretreatment of tissue sections. Am J Pathol 133:150–162Google Scholar
  31. 31.
    Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y (1988) Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 77:113–119Google Scholar
  32. 32.
    Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y (1988) A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrted by β protein immunostaining. Acta Neuropathol 76:541–549Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • R. Doi-Yi
    • 1
  • T. Kitamoto
    • 1
  • J. Tateishi
    • 1
  1. 1.Department of Neuropathology, Neurological Institute, Faculty of MedicineKyushu UniversityFukuokaJapan

Personalised recommendations